AryoSeven

AryoSeven is a trade name for drug form of blood factor VII which is manufacturing by AryoGen Biopharma.

Description
AryoSeven is a glycoprotein which is produced by recombinant DNA technology and is formulated totally similar to the original drug with the name of Novoseven. The product is actually the first biosimilar or biogeneric of the above mentioned drug with a totally approved similarity. This biomedicine is produced in Babay Hamster Kidney (BHK)cells and has similar characteristics and functions with the native blood factor VII.

Mechanism of action
This drug is caused activation of extrinsic pathway of blood coagulation.

Indications
In patients with born hemophilia type A and B which suffer from deficiency of factor VIII and IX these two factors are administrated for controlling bleeding or as prophylaxis medication before starting surgeries. However after sometimes these patients develop neutralizing antibodies (NAb) against the drug. These NAbs are increasd during time and cause to inhibit action of medicine (coagulation)in the patient's body. The AryoSeven, which is activated form factor VII, is bypassing factor VIII and IX and cause to coagulation of blood without need to factor VIII and IX. This is very important and vital for such patients to shift to proper blood factors according to their level of NAbs. Other indications are including use for patients with acquired hemophilia, paitients with born deficiency of factor VII, patents with Glanzmann's thrombasthenia and off-lable uses for controlling acute bleedings due to traumas.

Dosage
Dose of administration is equal to 90 - 120 µg/kg of body mass. It is 90 µg/kg for first injection and 120 µg/kg for second and third injections.

Rote of administration
AryoSeven is administrated intravenously(IV) normally under physician supervisory.

Packing form
Aryoseven is a lyophilized powder packed in 1.2 mg vials. It is offered with a 2.2 ml water for injection vial.